{"disease":{"id":"relapsed-and-refractory","name":"relapsed and refractory"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07222761","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":915,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03433001","title":"A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone","phase":"","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06849921","title":"Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06153251","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT03029234","title":"Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03170882","title":"A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02223598","title":"A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Cleave Biosciences, Inc.","has_results":false},{"nct_id":"NCT03715478","title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Canadian Myeloma Research Group","has_results":false},{"nct_id":"NCT03477643","title":"Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT04930536","title":"Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03140943","title":"Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT04283006","title":"A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT06182696","title":"OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":83,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05719701","title":"Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05527275","title":"A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05585996","title":"Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05673967","title":"Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06103838","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00932698","title":"Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07055477","title":"A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03242460","title":"The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Kosin University Gospel Hospital","has_results":false},{"nct_id":"NCT06876142","title":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03416374","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02917941","title":"A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05530421","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04697940","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Han weidong","has_results":false},{"nct_id":"NCT03376958","title":"Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT03487133","title":"Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04776018","title":"A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03683277","title":"IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Intergroupe Francophone du Myelome","has_results":false},{"nct_id":"NCT05066022","title":"A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03836053","title":"Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06651853","title":"Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT07122609","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT02144038","title":"Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04169932","title":"The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Longyao Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT07234110","title":"CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05486975","title":"This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04626908","title":"Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT03624036","title":"Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT03661554","title":"BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"The Pregene (ShenZhen) Biotechnology Company, Ltd.","has_results":false},{"nct_id":"NCT04272775","title":"A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04017130","title":"A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":false},{"nct_id":"NCT05893693","title":"Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Aibin Liang，MD，Ph.D.","has_results":false},{"nct_id":"NCT06295549","title":"Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07198230","title":"Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Ting YANG","has_results":false},{"nct_id":"NCT05445765","title":"Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"iCell Gene Therapeutics","has_results":false},{"nct_id":"NCT03879382","title":"Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Hrain Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07234721","title":"SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}